Exchange: NASDAQ·Updated 07:53 PM EDT

NEO News

News
all
press releases
NeoGenomics to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced that the Company will participate in the Morgan Stanley 24th Annual Global Healthcare Conference, which is being held Sept. 1416, 2026, in New York, NY.Managements...
Business Wire
More News
Why Did SJM, REPL, NEO Stocks Surge To 52-Week Highs Today?
Earnings, drug development, and healthcare reimbursement fueled the stock rallies.
Stocktwits
NeoGenomics Receives Medicare Coverage for RaDaR ST for Immunotherapy Treatment Response Monitoring
NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, announced that its RaDaR ST molecular residual disease (MRD) assay has received expanded coverage from the Centers for Medicare & Medicaid Services' (CMS) Molecular Diagnostic...
Business Wire
NeoGenomics, Inc. (NEO) Hits Fresh High: Is There Still Room to Run?
NeoGenomics (NEO) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Zacks
NeoGenomics, Inc. (NEO) Hit a 52 Week High, Can the Run Continue?
NeoGenomics (NEO) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Zacks
Illumina, Inc. (ILMN) Hits Fresh High: Is There Still Room to Run?
Illumina (ILMN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Zacks
NeoGenomics Reports Second Quarter 2026 Results
NeoGenomics, Inc. (NASDAQ: NEO) (the Company), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced its second-quarter results for the period ended June 30, 2026. Financial Highlights For the three-month period ended June 30, 2026, as compared to the...
Business Wire
NeoGenomics Announces Settlement of Voluntary Disclosure to OIG-HHS
NeoGenomics, Inc. (the Company) (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced that it has finalized a civil settlement with the Department of Justice (DOJ) on behalf of the Office of Inspector General of the U.S. Department of...
Business Wire
PRPO vs. NEO: Which Cancer Diagnostics Stock Is the Better Buy?
Precipio and NeoGenomics take different approaches to cancer diagnostics, but which oncology stock looks more compelling now? Let's dive in.
Zacks
NeoGenomics Launches FDA-Approved PTEN IHC Companion Diagnostic for Prostate Cancer
NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the launch of PTEN IHC CDx, the first immunohistochemistry (IHC) companion diagnostic test approved by the U.S. Food and Drug Administration (FDA) for patients with...
Business Wire

Advertisement|Remove ads.